The Greek-German GLIOMARK consortium will be present at the EIT Innovator´s Summit, taking place in Berlin on 10th-11th September, 2018. With Athens-based ProActina SA and Berlin-based ConsulTech GmbH two small and medium-sized companies (SMEs) have been cooperating intensively for three years now in the development of a diagnostic agent for rare high-grade brain tumors (gliomas). Now, the first clinical success of this Greek-German collaboration can be announced: the clinical study Gliomark1 (phase II) has been successfully completed.
At EIT innovator´s summit will take part around 1000 top innovators, investors and corporates. They will gather for hands-on workshops, relevant matchmaking, a showcase by European top innovators and inspiring talks. Dr. Alexandros Strongilos (CEO of ProActina) and Dr. Daniel Schubart (CEO of ConsulTech) will take this opportunity to meet peers, pitch the project, present their ideas in front of top investors, exchange experiences and find new partnerships.